The Global Respiratory Inhalers Market, by Product
Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit
Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and
Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive
Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis),
by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 27,424.4 million in 2016 and is projected to exhibit a CAGR of 5.7% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.
Chronic obstructive pulmonary disease
(COPD) is a life-threatening disease affecting the lungs characterized
by acute breathlessness. In 2015, it was estimated that around 3 million
deaths occurred due to sever Chronic Obstructive Pulmonary Disease
(COPD), with 90% fatalities reported in low and middle income countries.
The two most common forms of COPD include Chronic Bronchitis and
Emphysema. According to American Lung Association (ALA), in 2011, over
24 million people in the U.S. suffered from COPD, including 10 million
Chronic Bronchitis and over 4.7 million Emphysema cases. The major
reason for chronic obstructive pulmonary disease is exposure to tobacco
smoke through active or passive smoking. Most chronic obstructive
pulmonary disease cases are preventable by avoiding tobacco smoking.
However, countries need to adopt the WHO Framework Convention on Tobacco
Control (WHO-FCTC) and follow the MPOWER package of measures so that
non-smoking becomes the norm globally.
Asthma is also one of the prime
conditions leading to respiratory, disease which is characterized by
recurring attacks of panting and wheezing. The severity and frequency of
asthma varies according to individual. According to Center for Disease
Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in
the U.S. were suffering from asthma. Under 18 age group, 6.2 million
people suffered from asthma. Each year asthma accounts for 14.2 million
physician office visits, and 1.8 million emergency visits.
Browse 32 Market Data Tables and 25 Figures spread through 195 Pages and in-depth TOC on Respiratory Inhalers Market by Product
Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit
Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and
Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive
Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis),
by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025
To know the latest trends and insights prevalent in the Respiratory Inhalers Market, click the link below:
According to Canadian Lung Association
(CLA), in 2014, 2.5 million people in Canada suffered from asthma,
including 1 million males and 1.4 million females. The number of people
having asthma was 0.9 million in Ontario, 0.6 million in Quebec, 0.3
million in British Colombia, and Alberta states of Canada. According to
Health and Safety Executive (HSE), an U.K based organization, each year
in the U.K 200 to 300 new cases of occupational asthma, 4,000 COPD
deaths, 200 to 300 new cases of Pneumoconiosis, and 20-50 new cases of
Silicosis were reported. In 2015, it also reported 2,542 mesothelioma
and 467 asbestos related deaths.
Inhalers play a pivotal role in
treatment of asthma and chronic obstructive pulmonary disease. The
importance of the inhalation is delivery of medicines that directly acts
on air passage and lungs. This signifies the higher concentrations of
drug at target site, with lower systemic exposure thus also have low
adverse effects than the oral or intravenous administration of drug. The
drawback of inhalers are that it leads to suboptimal use and low
efficacy. The design of inhalers also plays an important role in drug
deposition, the characteristics of the inhaled medicine, and on the
ability of the patient to use the device.
Key takeaways of the market:
- The global respiratory inhalers market is expected to expand at a CAGR of 7% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
- Asthma, a therapeutic application segment is expected to dominate the market throughout the forecast period with increasing prevalence of asthma
- North America is expected to dominate the market, owing to the increasing usage of smart inhalers during the forecast period
- Some of the major players involved in global respiratory inhalers market are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.
- The key players are focusing on combinational therapies, which will drive the market forward
About Coherent Market Insights:
Coherent Market Insights is a prominent
market research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging
market trends, technologies, and potential absolute dollar opportunity.
Contact Us:Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
No comments:
Post a Comment